Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031

Eli Lilly has crushed broader equities in recent years. The company's leadership in the fast-growing GLP-1 market grants it attractive medium-term prospects.

The Motley Fool • 9 hours ago

Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%

A failed cholesterol trial from Novartis (NYSE:NVS | NVS Price Prediction) is dragging the Lp(a) drug class lower and hitting Amgen (NASDAQ:AMGN) harder than any large-cap peer in Tuesday trading.

24/7 Wall Street • a day ago

Wall Street Bulls Look Optimistic About Lilly (LLY): Should You Buy?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Sep 8, 2026

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.

Zacks Investment Research • 18 hours ago

Cholesterol drug setback casts doubt over multibillion-dollar race

Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.

CNBC • Sep 8, 2026

Lilly Builds Neuroscience into a New Long-Term Growth Driver

Lilly is expanding its neuroscience pipeline through strong growth and M&A, aiming to build a new long-term driver beyond cardiometabolic therapies.

Zacks Investment Research • Sep 8, 2026

Novo Nordisk's Semaglutide Meets Goal in Pediatric Obesity Study

NVO's semaglutide cuts BMI in children with obesity in phase III study, with 40.4% no longer classified as having obesity after 68 weeks.

Zacks Investment Research • Sep 8, 2026

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

Eli Lilly's most important drugs right now are Mounjaro, Zepbound, and, to a lesser degree, Foundayo.  The company's dominant GLP-1 weight-loss drugs are facing material competition and have time-limited patent protection.

The Motley Fool • Sep 7, 2026

Here's Why Eli Lilly (LLY) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Sep 7, 2026

Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

Zacks Investment Research • Sep 7, 2026